U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Digestive System Carcinoma

MedGen UID:
1663290
•Concept ID:
C4726547
•
Neoplastic Process
Synonym: Refractory Gastrointestinal System Carcinoma

Definition

A carcinoma hat arises from any part of the digestive system and is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Digestive System Carcinoma

Professional guidelines

PubMed

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ
Oncologist 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. PMID: 37390492Free PMC Article
Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma.
Dondossola D, Ghidini M, Grossi F, Rossi G, Foschi D
World J Gastroenterol 2020 Jul 7;26(25):3542-3561. doi: 10.3748/wjg.v26.i25.3542. PMID: 32742125Free PMC Article
Cryotherapy in the management of premalignant and malignant conditions of the esophagus.
Lal P, Thota PN
World J Gastroenterol 2018 Nov 21;24(43):4862-4869. doi: 10.3748/wjg.v24.i43.4862. PMID: 30487696Free PMC Article

Recent clinical studies

Etiology

Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms.
Kaur J, Vijayvergia N
Curr Oncol 2023 Sep 21;30(9):8653-8664. doi: 10.3390/curroncol30090627. PMID: 37754542Free PMC Article
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).
Lee CK, Chon HJ, Cheon J, Lee MA, Im HS, Jang JS, Kim MH, Park S, Kang B, Hong M, Kim JW, Park HS, Kang MJ, Park YN, Choi HJ
Lancet Gastroenterol Hepatol 2023 Jan;8(1):56-65. Epub 2022 Oct 31 doi: 10.1016/S2468-1253(22)00335-1. PMID: 36328033
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z, Xu A, Chen X, Zhou C, Ren Z, Yang L, Xu L, Bai Y, Chen L, Li J, Pan H, Cao B, Fang W, Wu W, Wang G, Cheng Y, Yu Z, Zhu X, Jiang D, Lu Y, Wang H, Xu J, Bai L, Liu Y, Lin H, Wu C, Zhang Y, Yan P, Jin C, Zou J
Lancet Gastroenterol Hepatol 2021 Jul;6(7):559-568. Epub 2021 May 8 doi: 10.1016/S2468-1253(21)00109-6. PMID: 33971141
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT
J Clin Oncol 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15 doi: 10.1200/JCO.2017.76.6212. PMID: 30110194Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052

Diagnosis

Intrahepatic cholangiocarcinoma: Evolving strategies in management and treatment.
Bragazzi MC, Venere R, Ribichini E, Covotta F, Cardinale V, Alvaro D
Dig Liver Dis 2024 Mar;56(3):383-393. Epub 2023 Sep 16 doi: 10.1016/j.dld.2023.08.052. PMID: 37722960
Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the Joint Meeting of the International Association of Pancreatology (IAP) & the Japan Pancreas Society (JPS) 2022 in Kyoto.
Hashimoto D, Satoi S, Fujii T, Sho M, He J, Hackert T, Del Chiaro M, Jang JY, Gulla A, Yoon YS, Shan YS, Lou W, Valente R, Furuse J, Oba A, Nagai M, Terai T, Tanaka H, Sakai A, Yamamoto T, Yamaki S, Matsumoto I, Murakami Y, Takaori K, Takeyama Y
Pancreatology 2023 Sep;23(6):682-688. Epub 2023 Jul 20 doi: 10.1016/j.pan.2023.07.005. PMID: 37507301
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z, Xu A, Chen X, Zhou C, Ren Z, Yang L, Xu L, Bai Y, Chen L, Li J, Pan H, Cao B, Fang W, Wu W, Wang G, Cheng Y, Yu Z, Zhu X, Jiang D, Lu Y, Wang H, Xu J, Bai L, Liu Y, Lin H, Wu C, Zhang Y, Yan P, Jin C, Zou J
Lancet Gastroenterol Hepatol 2021 Jul;6(7):559-568. Epub 2021 May 8 doi: 10.1016/S2468-1253(21)00109-6. PMID: 33971141
Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma.
Dondossola D, Ghidini M, Grossi F, Rossi G, Foschi D
World J Gastroenterol 2020 Jul 7;26(25):3542-3561. doi: 10.3748/wjg.v26.i25.3542. PMID: 32742125Free PMC Article
Genomic and transcriptional alterations of cholangiocarcinoma.
Ito T, Sakurai-Yageta M, Goto A, Pairojkul C, Yongvanit P, Murakami Y
J Hepatobiliary Pancreat Sci 2014 Jun;21(6):380-7. Epub 2014 Feb 13 doi: 10.1002/jhbp.67. PMID: 24532422

Therapy

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ
Oncologist 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. PMID: 37390492Free PMC Article
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Subbiah V, Iannotti NO, Gutierrez M, Smith DC, Féliz L, Lihou CF, Tian C, Silverman IM, Ji T, Saleh M
Ann Oncol 2022 May;33(5):522-533. Epub 2022 Feb 14 doi: 10.1016/j.annonc.2022.02.001. PMID: 35176457
CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase.
Lin Y, Cai Q, Chen Y, Shi T, Liu W, Mao L, Deng B, Ying Z, Gao Y, Luo H, Yang X, Huang X, Shi Y, He R
Hepatology 2022 Jan;75(1):28-42. Epub 2021 Dec 5 doi: 10.1002/hep.32099. PMID: 34387870
SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway.
Zhou C, Liu C, Liu W, Chen W, Yin Y, Li CW, Hsu JL, Sun J, Zhou Q, Li H, Hu B, Fu P, Atyah M, Ma Q, Xu Y, Dong Q, Hung MC, Ren N
Theranostics 2020;10(10):4627-4643. Epub 2020 Mar 25 doi: 10.7150/thno.42869. PMID: 32292519Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052

Prognosis

Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms.
Kaur J, Vijayvergia N
Curr Oncol 2023 Sep 21;30(9):8653-8664. doi: 10.3390/curroncol30090627. PMID: 37754542Free PMC Article
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z, Xu A, Chen X, Zhou C, Ren Z, Yang L, Xu L, Bai Y, Chen L, Li J, Pan H, Cao B, Fang W, Wu W, Wang G, Cheng Y, Yu Z, Zhu X, Jiang D, Lu Y, Wang H, Xu J, Bai L, Liu Y, Lin H, Wu C, Zhang Y, Yan P, Jin C, Zou J
Lancet Gastroenterol Hepatol 2021 Jul;6(7):559-568. Epub 2021 May 8 doi: 10.1016/S2468-1253(21)00109-6. PMID: 33971141
Mutational spectrum and precision oncology for biliary tract carcinoma.
Lin J, Cao Y, Yang X, Li G, Shi Y, Wang D, Long J, Song Y, Mao J, Xie F, Bai Y, Zhang L, Yang X, Wan X, Wang A, Guan M, Zhao L, Hu K, Pan J, Huo L, Lu X, Mao Y, Sang X, Zhang H, Wang K, Wang X, Zhao H
Theranostics 2021;11(10):4585-4598. Epub 2021 Mar 4 doi: 10.7150/thno.56539. PMID: 33754015Free PMC Article
SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway.
Zhou C, Liu C, Liu W, Chen W, Yin Y, Li CW, Hsu JL, Sun J, Zhou Q, Li H, Hu B, Fu P, Atyah M, Ma Q, Xu Y, Dong Q, Hung MC, Ren N
Theranostics 2020;10(10):4627-4643. Epub 2020 Mar 25 doi: 10.7150/thno.42869. PMID: 32292519Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052

Clinical prediction guides

Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms.
Kaur J, Vijayvergia N
Curr Oncol 2023 Sep 21;30(9):8653-8664. doi: 10.3390/curroncol30090627. PMID: 37754542Free PMC Article
Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.
Limousin W, Laurent-Puig P, Ziol M, Ganne-Carrié N, Nahon P, Ait-Omar A, Seror O, Sidali S, Campani C, Blanc P, Lermine A, Marisa L, Zucman-Rossi J, Nault JC
J Hepatol 2023 Dec;79(6):1450-1458. Epub 2023 Aug 28 doi: 10.1016/j.jhep.2023.08.017. PMID: 37647991
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ
Oncologist 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. PMID: 37390492Free PMC Article
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).
Lee CK, Chon HJ, Cheon J, Lee MA, Im HS, Jang JS, Kim MH, Park S, Kang B, Hong M, Kim JW, Park HS, Kang MJ, Park YN, Choi HJ
Lancet Gastroenterol Hepatol 2023 Jan;8(1):56-65. Epub 2022 Oct 31 doi: 10.1016/S2468-1253(22)00335-1. PMID: 36328033
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052

Recent systematic reviews

Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.
Catenacci DV, Chao J, Muro K, Al-Batran SE, Klempner SJ, Wainberg ZA, Shah MA, Rha SY, Ohtsu A, Liepa AM, Knoderer H, Chatterjee A, Van Cutsem E
Oncologist 2021 Oct;26(10):e1704-e1729. Epub 2021 Sep 3 doi: 10.1002/onco.13907. PMID: 34288262Free PMC Article
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y, Moldovan M, Chang Lee R, Hsieh AH, Townsend A, Price T
Cochrane Database Syst Rev 2020 Nov 19;11(11):CD012078. doi: 10.1002/14651858.CD012078.pub2. PMID: 33210731Free PMC Article
Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review.
Schizas D, Mastoraki A, Bagias G, Patras R, Moris D, Lazaridis II, Arkadopoulos N, Felekouras E
J BUON 2019 Mar-Apr;24(2):415-423. PMID: 31127985

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...